Krsnaa Diagnostics

Quick check

The five things to look at first. Open one for more.

• DebtAdequate safetyRated A by ICRA.
• ResultsProfit fallingIn the Jun 2026 quarter, sales rose 20% and profit fell 20% from a year earlier.
• DilutionRaise plannedNo new shares issued in the last year, so existing shareholders' slices were not cut.
• PromotersSteadyThe promoters (founders or parent) own 27% of the company, about the same as in Jun 2025.
• ValuationCheap vs its pastThe share trades at 16.6 times its yearly earnings (P/E), cheaper than 100% of the time in the last 4 years. Its usual P/E is about 29.

Krsnaa Diagnostics against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

• Valuation (P/E)16.6 against a typical 20.5: cheaper than most peers (1st = cheapest).9th of 34
• Sales growth+19.9% against a typical +19.1% from a year earlier.15th of 31
• Profit growth−20% against a typical +25.2% from a year earlier.16th of 24
• Share price, 3 months−7% against a typical −7.5%.14th of 33
• Size₹ 1,616.8 Cr. market value against a typical ₹ 83 Cr. (1st = largest).6th of 34

Exchange filings and their impact on the company.

• 22 Oct 2026Press ReleaseLow impactPositivePrice +0.1% that day
  Krsnaa to pilot AZmed AI for 5m annual X-rays to boost reporting speed and scale.

  Krsnaa Diagnostics announced a strategic AI collaboration with Paris-based AZmed to evaluate its AZtrauma AI tool for detecting fractures, joint effusions and dislocations on X-rays. Krsnaa reports over 5 million X-rays annually across 2,000+ X-ray centres and a large teleradiology hub. The pilot aims to improve reporting efficiency and radiologist capacity to support scalable growth, with benefits dependent on evaluation success and regulatory approvals.

  Full analysisFiling
• 13 Oct 2026Allotment of SecuritiesMedium impactPositivePrice −1.2% on 14 Oct
  Promoter group allotted 16.21 lakh warrants at Rs 566, bringing Rs 22.9 cr now and up to Rs 91.7 cr on conversion.

  Krsnaa Diagnostics allotted 16,21,000 fully convertible warrants at Rs 566 per warrant to promoter group entities on October 13, 2026, after board, shareholder and exchange approvals. The company received 25% upfront, or Rs 22.94 crore, with the balance 75% payable on conversion into one equity share per warrant within 18 months for a total of Rs 91.75 crore. There is no change in paid-up share capital yet; the funds strengthen equity and will cause about 5% dilution if fully converted.

  Full analysisFiling
• 9 Oct 2026General UpdatesMedium impactPositivePrice −0.6% on 12 Oct
  BSE nod for 16.21 lakh promoter warrants at Rs 566 brings ~Rs 91.7 cr equity inflow at a premium.

  Krsnaa Diagnostics received corrected in-principle approval from BSE for issuing 16,21,000 convertible warrants at Rs 566 each to its promoter and promoter group on a preferential basis. The issue would raise about Rs 91.7 crore, a ~6% premium to the current price of ~Rs 532-538. If subscribed and converted, the promoter funding will boost equity, help fund expansion and reduce debt, with about 5% equity dilution.

  Full analysisFiling
• 8 Oct 2026General UpdatesLow impactPositivePrice +0.7% on 9 Oct
  NSE cleared listing of 16.21 lakh shares on warrant conversion, implying ~Rs65-90cr equity inflow and ~5% dilution.

  Krsnaa Diagnostics received NSE in-principle approval for listing of 16,21,000 equity shares of Rs 5 each to be issued on conversion of preferential warrants. The approval is procedural and subject to listing application and statutory compliances before allotment. The conversion implies about 5% equity dilution and should bring in fresh equity to support growth and strengthen the balance sheet.

  Full analysisFiling

Results dates and other board meetings. Full calendar

Compounded yearly rates over each period.

Listed companies in the same business.

Rajendra Khivraj Mutha

Chairman and Whole Time Director

Mitesh Dave

Group Chief Executive Officer

Chandra Prakash Singh

Interim Chief Financial Officer

Sujoy Sudipta Bose

Company Secretary, Compliance Officer

Yash Prithviraj Mutha

Managing Director, Executive Director

Pallavi Shantilal Bhatevara

Whole Time Director